Broking house, Karvy Stock Broking is bullish on Dr Reddy’s Laboratories and believes that it would be a market performer with a target price of Rs 84...
Dr Reddy's Laboratories Ltd today got the final approval for Ondansetron Hydrochloride, the generic equivalent of the blockbuster drug `Zofran', from ...
VC & CEO of Dr Reddy's Laboratories, GV Prasad comments on getting the exclusivity for Ondansetron soon after the rights for Simvastatin and Proscar g...
Dr Reddy has crossed a billion dollars in revenues, and that makes it the second Indian company after Ranbaxy to scale the magic figure, reports CNBC-...
Dr Reddy's is looking at acquisition in European markets. CEO Satish Reddy added the company is also gearing up for the launch of their new poly pill,...
Researchers at the University of Auckland have teamed up with Dr Reddy's Laboratories, Hyderabad to undertake trials of a new Polypill that could prov...
In Europe they are called biosimilars and the us FDA calls them follow on protein products but copies of biotech drugs could be the next big opportuni...